SCHEMBL8544715

SCHEMBL8544715

O=c1[nH]nc(Cl)n1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 6/20 0.46
HPGD P15428 5/20 0.46
POLB P06746 2/20 0.46
CYP3A4 P08684 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 3/20 0.45
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PNP P00491 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
P2RX4 Q99571 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12692930 0.81 KDM4E (0.66) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL25271993 0.81 GSK3A (0.46) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL9354106 0.79 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDPOLBSMN1; SMN2
SCHEMBL6502344 0.79 ALDH1A1 (0.51) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL7834131 0.78 HPGD (0.50) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL3285126 0.78 ALDH1A1 (0.50) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL9354368 0.78 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL11967273 0.77 TLR7 (0.46) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL21407925 0.75 KDM4E (0.54) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL2337883 0.75 HPGD (0.58) GSK3AGSK3BALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2025-06-05 US disclosed
EP-4486743-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-01-08 EP disclosed
CN-118765280-A RIP1 modulators, their preparation and use 维泰瑞隆有限公司 2024-10-11 CN disclosed
WO-2023160638-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-08-31 WO disclosed
EP-0661262-B1 Halogenated Triazolinones BAYER AG (DE) 1998-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF RIPK1, RIPK2, RIPK3 GSK3A 1234/4885GSK3B 1049/4885ALDH1A1 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.